ArticleCell2021
Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia.
Open access · bronzeAbstract read
In one paragraph
Article in Cell, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
4.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 82 citations in OpenAlex.
- Switching Spike Plasticity Shapes ACE2 Engagement Across SARS-CoV-2 Variants.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Zooming into Disease at the Nanoscale: High-Speed Atomic Force Microscopy in Biomedical Discovery.ACS nano · 2026Review
- IgG-Bridging-Seeded Synergistic Aggregation of SARS-CoV-2 Spikes Underlies Potent Neutralization by a Low-Affinity Antibody.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- LL-37 Inhibits TMPRSS2-Mediated S2' Site Cleavage and SARS-CoV-2 Infection but Not Omicron Variants.Cell proliferation · 2025Article
- MERS-related coronavirus circulating in pangolins exhibits strong fusogenicity in human cells and high sensitivity to fusion inhibitors.Cell reports. Medicine · 2025Article
- A combinatorial and computational Tandem approach towards a universal therapeutics against ACE2-mediated coronavirus infections.iScience · 2025Article
- Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants.Communications biology · 2025Article
- Structural Immunology of SARS-CoV-2.Immunological reviews · 2025Review
- Significant association between asthma and a lower risk of mortality among COVID-19 patients in Spain: A meta-analysis.Qatar medical journal · 2024Review
- Differences in syncytia formation by SARS-CoV-2 variants modify host chromatin accessibility and cellular senescence via TP53.Cell reports · 2023Article
- Porcine deltacoronavirus resists antibody neutralization through cell-to-cell transmission.Emerging microbes & infections · 2023Article
- Defining neutralization and allostery by antibodies against COVID-19 variants.Nature communications · 2023Article
- Rare antibody phage isolation and discrimination (RAPID) biopanning enables identification of high-affinity antibodies against challenging targets.Communications biology · 2023Article
- SARS-CoV-2 Syncytium under the Radar: Molecular Insights of the Spike-Induced Syncytia and Potential Strategies to Limit SARS-CoV-2 Replication.Journal of clinical medicine · 2023Review
- A high-throughput screening system for SARS-CoV-2 entry inhibition, syncytia formation and cell toxicity.Biological procedures online · 2023Article
- An mRNA-based T-cell-inducing antigen strengthens COVID-19 vaccine against SARS-CoV-2 variants.Nature communications · 2023Article
- SARS-CoV-2 spike host cell surface exposure promoted by a COPI sorting inhibitor.Acta pharmaceutica Sinica. B · 2023Article
- Positive-strand RNA viruses-a Keystone Symposia report.Annals of the New York Academy of Sciences · 2023Article
- Targeted protein S-nitrosylation of ACE2 inhibits SARS-CoV-2 infection.Nature chemical biology · 2023Article
- Human antibody BD-218 has broad neutralizing activity against concerning variants of SARS-CoV-2.International journal of biological macromolecules · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors at 5 institutions in 3 countries.
Daniel AsarnowDepartment of Biochemistry and Biophysics, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Bei WangSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Wen-Hsin LeeSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Yuanyu HuSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Ching-Wen HuangSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Bryan FaustDepartment of Biochemistry and Biophysics, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Patricia Miang Lon NgSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Eve Zi Xian NgohSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Markus BohnQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA; Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA.
David BulkleyDepartment of Biochemistry and Biophysics, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA.
Andrés PizzornoCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Beatrice AryQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA; Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA.
Hwee Ching TanSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Chia Yin LeeSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Rabiatul Adawiyah MinhatSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Olivier TerrierCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France.
Mun Kuen SohSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Frannie Jiuyi TeoSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Yvonne Yee Chin YeapSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Shirley Gek Kheng SeahBiological Defence Program, DSO National Laboratories, 27 Medical Drive, Singapore 117510, Singapore.
Conrad En Zuo ChanBiological Defence Program, DSO National Laboratories, 27 Medical Drive, Singapore 117510, Singapore.
Emily ConnellyDepartment of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA.
Nicholas J YoungDepartment of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA.
Sebastian Maurer-StrohBioinformatics Institute, Agency for Science, Technology and Research (A(∗)STAR), 30 Biopolis Street, Matrix, Singapore 138671, Singapore; Infectious Diseases Laboratories (ID Labs), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore; Department of Biological Sciences, Faculty of Science, National University of Singapore, Singapore 117558, Singapore.
Laurent ReniaSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore; Infectious Diseases Laboratories (ID Labs), Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore.
Brendon John HansonBiological Defence Program, DSO National Laboratories, 27 Medical Drive, Singapore 117510, Singapore.
Manuel Rosa-CalatravaCIRI, Centre International de Recherche en Infectiologie (Team VirPath), Université de Lyon, INSERM U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, 69007 Lyon, France; VirNext, Faculté de Médecine RTH Laennec, Université Claude Bernard Lyon 1, Université de Lyon, Lyon, France.
Aashish ManglikQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA; Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA; Department of Anesthesia and Perioperative Care, UCSF, San Francisco, CA, USA. Electronic address: aashish.manglik@ucsf.edu.
Yifan ChengDepartment of Biochemistry and Biophysics, University of California, San Francisco (UCSF) School of Medicine, San Francisco, CA, USA; QBI COVID-19 Research Group (QCRG), San Francisco, CA, USA; Howard Hughes Medical Institute, UCSF, San Francisco, CA, USA. Electronic address: ycheng@ucsf.edu.
Charles S CraikQBI COVID-19 Research Group (QCRG), San Francisco, CA, USA; Department of Pharmaceutical Chemistry, University of California, San Francisco (UCSF), San Francisco, CA, USA. Electronic address: charles.craik@ucsf.edu.
Cheng-I WangSingapore Immunology Network, Agency for Science, Technology and Research (A(∗)STAR), 8A Biomedical Grove, Immunos, Singapore 138648, Singapore. Electronic address: wang_chengi@immunol.a-star.edu.sg.
Agency for Science, Technology and Research · SGUniversity of California, San Francisco · USDSO National Laboratories · SGUniversité Claude Bernard Lyon 1 · FRHoward Hughes Medical Institute · US
Funding
X-ray Screening and Rapid Structure DeterminationP50AI150476 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KROGAN, NEVAN J · 2019 to 2021
$14.4MSTRUCTURAL BIOLOGY TRAINING PROGRAMT32GM008284 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KORTEMME, TANJA · 1988 to 2022
$10.1MMicrobial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5MAcquisition of an electron microscope for high-resolution single particle cryo-EMS10OD021741 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2016 to 2016
$2.0MLinux cluster for near atomic resolution single particle cryo-EMS10OD020054 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHENG, YIFAN · 2015 to 2015
$456kHoward Hughes Medical InstituteNIAID NIH HHS P50 AI150476NIAID NIH HHS T32 AI060537NIGMS NIH HHS T32 GM008284NIH HHS S10 OD020054NIH HHS S10 OD021741
Abstract
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is initiated by binding of the viral Spike protein to host receptor angiotensin-converting enzyme 2 (ACE2), followed by fusion of viral and host membranes. Although antibodies that block this interaction are in emergency use as early coronavirus disease 2019 (COVID-19) therapies, the precise determinants of neutralization potency remain unknown. We discovered a series of antibodies that potently block ACE2 binding but exhibit divergent neutralization efficacy against the live virus. Strikingly, these neutralizing antibodies can inhibit or enhance Spike-mediated membrane fusion and formation of syncytia, which are associated with chronic tissue damage in individuals with COVID-19. As revealed by cryoelectron microscopy, multiple structures of Spike-antibody complexes have distinct binding modes that not only block ACE2 binding but also alter the Spike protein conformational cycle triggered by ACE2 binding. We show that stabilization of different Spike conformations leads to modulation of Spike-mediated membrane fusion with profound implications for COVID-19 pathology and immunity.
Indexed as
Angiotensin-Converting Enzyme 2AnimalsAntibodies, NeutralizingAntigen-Antibody ComplexBinding SitesCHO CellsCOVID-19CricetinaeCricetulusCryoelectron MicroscopyGiant CellsHumansMembrane FusionPeptide LibraryProtein BindingProtein DomainsAngiotensin-Converting Enzyme 2Antibodies, NeutralizingAntigen-Antibody ComplexPeptide LibrarySpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2coronavirusCOVID-19phage displayreceptor binding domain (RBD)recombinant monoclonal antibodySARS-CoVSARS-CoV-2Spike proteinsyncytia
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.